SECURITIES AND EXCHANGE COMMISSION
                             Washington, D. C. 20549


                                    FORM 8-K


                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):  April 21, 2005


                                   INYX, INC.
             (Exact name of registrant as specified in its charter)

Nevada                              333-83152                  75-2870720
------                              ---------                  ----------
(State or other jurisdiction       (Commission              (I.R.S. Employer
   of incorporation)               File Number)            Identification No.)

                825 Third Avenue, 40th Floor, New York, NY 10022
                ------------------------------------------------
               (Address of principal executive offices) (Zip Code)
       Registrant's telephone number, including area code: (212) 838-1111

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))



                                       1
<PAGE>

Item 1.01 Entry into a Material Definitive Agreement

      On April 21, 2005, Registrant received final approval and delivery of a
contract (originally signed on March 18, 2005) with Generics (UK) Ltd., a Unit
of Merck Generics Group, to produce non-ozone-depleting HFA Salbutamol Asthma
inhaler. The contract is for an initial term of four years, with automatic
renewal provisions, and is expected to produce initial annual revenues to
Registrant of approximately $7.5 million.

Item 7.01 Regulation FD Disclosure

      On April 21, 2005, Registrant issued a press release disclosing the
Generics (UK), Ltd. contract. Such press release is contained in Exhibit 99.1
hereto, which is being furnished, and shall not be deemed to be "filed", with
the SEC. Such exhibit shall not be incorporated by reference into any filing of
the Registrant with the SEC, whether made before or after the date hereof,
regardless of any general incorporation language in such filings.

Item 9.01. Financial Exhibits, Pro Forma Financial Information and Exhibits.

*10.37.1   Manufacturing and Supply Agreement with Generics (UK), Ltd., dated
           April 21, 2005.

99.1       Press Release disclosing that Inyx has been selected by Generics
           (UK), Ltd., a Unit of Merck Generics to produce non-ozone-depleting
           HFA Salbutamol Asthma inhaler.

-------------------
* - Confidentiality has been requested with respect to certain portions of this
Agreement.


                                   SIGNATURES

      Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            INYX, INC.



                                            By:  /s/ Jack Kachkar
                                                 -------------------------------
                                                 Jack Kachkar, Chairman and CEO

Dated: April 25, 2005


                                       2
<PAGE>

                                INDEX TO EXHIBITS

*10.37.1   Manufacturing and Supply Agreement with Generics (UK), Ltd., dated
           April 21, 2005.

99.1       Press Release disclosing that Inyx has been selected by Generics
           (UK), Ltd., a Unit of Merck Generics to produce non-ozone-depleting
           HFA Salbutamol Asthma inhaler.

-------------------
* - Confidentiality has been requested with respect to certain portions of this
Agreement.


                                       3
{"company-data": {"conformed-name": "INYX INC", "cik": "0001114241", "assigned-sic": "2834", "irs-number": "752870720", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-83152", "film-number": "05770536"}, "business-address": {"street1": "825 THIRD AVENUE", "street2": "40TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10022", "phone": "212-838-1111"}, "mail-address": {"street1": "825 THIRD AVENUE", "street2": "40TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10022"}, "former-company": {"former-conformed-name": "DOBLIQUE INC", "date-changed": "20000510"}}
SECURITIES AND EXCHANGE COMMISSION
                             Washington, D. C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  April 21, 2005

                                   INYX, INC.
             (Exact name of registrant as specified in its charter)

Nevada                              333-83152                  75-2870720
------                              ---------                  ----------
(State or other jurisdiction       (Commission              (I.R.S. Employer
   of incorporation)               File Number)            Identification No.)

                825 Third Avenue, 40th Floor, New York, NY 10022
                ------------------------------------------------
               (Address of principal executive offices) (Zip Code)
       Registrant's telephone number, including area code: (212) 838-1111

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

                                       1
Item 1.01 Entry into a Material Definitive Agreement

      On April 21, 2005, Registrant received final approval and delivery of a
contract (originally signed on March 18, 2005) with Generics (UK) Ltd., a Unit
of Merck Generics Group, to produce non-ozone-depleting HFA Salbutamol Asthma
inhaler. The contract is for an initial term of four years, with automatic
renewal provisions, and is expected to produce initial annual revenues to
Registrant of approximately $7.5 million.

Item 7.01 Regulation FD Disclosure

      On April 21, 2005, Registrant issued a press release disclosing the
Generics (UK), Ltd. contract. Such press release is contained in Exhibit 99.1
hereto, which is being furnished, and shall not be deemed to be "filed", with
the SEC. Such exhibit shall not be incorporated by reference into any filing of
the Registrant with the SEC, whether made before or after the date hereof,
regardless of any general incorporation language in such filings.

Item 9.01. Financial Exhibits, Pro Forma Financial Information and Exhibits.

*10.37.1   Manufacturing and Supply Agreement with Generics (UK), Ltd., dated
           April 21, 2005.

99.1       Press Release disclosing that Inyx has been selected by Generics
           (UK), Ltd., a Unit of Merck Generics to produce non-ozone-depleting
           HFA Salbutamol Asthma inhaler.

-------------------
* - Confidentiality has been requested with respect to certain portions of this
Agreement.

                                   SIGNATURES

      Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            INYX, INC.

                                            By:  /s/ Jack Kachkar
                                                 -------------------------------
                                                 Jack Kachkar, Chairman and CEO

Dated: April 25, 2005

                                       2
INDEX TO EXHIBITS

*10.37.1   Manufacturing and Supply Agreement with Generics (UK), Ltd., dated
           April 21, 2005.

99.1       Press Release disclosing that Inyx has been selected by Generics
           (UK), Ltd., a Unit of Merck Generics to produce non-ozone-depleting
           HFA Salbutamol Asthma inhaler.

-------------------
* - Confidentiality has been requested with respect to certain portions of this
Agreement.

                                       3